Cargando…

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization

Mostrar otras versiones (1)

BACKGROUND: The variant of concern, Omicron, has become the sole circulating SARS-CoV-2 variant for the past several months. Omicron subvariants BA.1, BA.2, BA.3, BA.4, and BA.5 evolved over the time, with BA.1 causing the largest wave of infections globally in December 2021– January 2022. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morris, C. Paul, Eldesouki, Raghda E., Sachithanandham, Jaiprasath, Fall, Amary, Norton, Julie M., Abdullah, Omar, Gallagher, Nicholas, Li, Maggie, Pekosz, Andrew, Klein, Eili Y., Mostafa, Heba H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516865/ https://www.ncbi.nlm.nih.gov/pubmed/36172137 http://dx.doi.org/10.1101/2022.09.20.22280154

Ejemplares similares

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C Paul, et al.
Publicado: (2022)

The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads
por: Fall, Amary, et al.
Publicado: (2022)

A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads
por: Fall, Amary, et al.
Publicado: (2022)

SARS-CoV-2 reinfections during the Delta and Omicron waves
por: Morris, C. Paul, et al.
Publicado: (2022)

Evaluation of Four Point of Care (POC) Antigen Assays for the Detection of the SARS-CoV-2 Variant Omicron
por: Hardick, Justin, et al.
Publicado: (2022)

Severity outcomes associated with SARS-CoV-2 XBB variants, an observational analysis
por: Klein, Eili Y., et al.
Publicado: (2023)

Sequence Proven Reinfections with SARS-CoV-2 at a Large Academic Center
por: Morris, C. Paul, et al.
Publicado: (2022)

Circulation of Enterovirus D68 during Period of Increased Influenza-Like Illness, Maryland, USA, 2021
por: Fall, Amary, et al.
Publicado: (2022)

Reduced control of SARS-CoV-2 infection is associated with lower mucosal antibody responses in pregnant women
por: St Clair, Laura A., et al.
Publicado: (2023)

Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals
por: Luo, Chun Huai, et al.
Publicado: (2021)

Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals
por: Huai Luo, Chun, et al.
Publicado: (2021)

Large Scale SARS-CoV-2 Molecular Testing and Genomic Surveillance Reveal Prolonged Infections, Protracted RNA shedding, and Viral Reinfections
por: Morris, C. Paul, et al.
Publicado: (2022)

Respiratory Adenovirus Quantification with a Droplet Digital Polymerase Chain Reaction (ddPCR) Assay
por: Abdullah, Omar, et al.
Publicado: (2023)

The circulation of Non-SARS-CoV-2 respiratory viruses and coinfections with SARS-CoV-2 during the surge of the Omicron variant
por: Eldesouki, Raghda E., et al.
Publicado: (2022)

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
por: Wang, Xue-Jun, et al.
Publicado: (2022)

Genomic evidence for reinfection with different Omicron subvariants
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Protection against Reinfection with the Omicron BA.2.75 Subvariant
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Detection of the Omicron BA.2.75 subvariant in Japan
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Immune Evasion of SARS-CoV-2 Omicron Subvariants
por: Ke, Hanzhong, et al.
Publicado: (2022)

Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Modelling the impact of the Omicron BA.5 subvariant in New Zealand
por: Lustig, Audrey, et al.
Publicado: (2023)

Omicron subvariant BA.5 efficiently infects lung cells
por: Hoffmann, Markus, et al.
Publicado: (2023)

Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants
por: Li, Yaning, et al.
Publicado: (2023)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Coding-Complete Genome Sequences of an Omicron Subvariant (BA.5.2.20) of SARS-CoV-2
por: Rhazzar, Zineb, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Moving targets: COVID-19 vaccine efficacy against Omicron subvariants
por: da Silva, Maria Karolaynne, et al.
Publicado: (2022)

Reinfections with Different SARS-CoV-2 Omicron Subvariants, France
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
por: Zhu, Ka-Li, et al.
Publicado: (2023)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Xbb subvariant of Omicron: Can the new wave sneak past your immune defense?
por: Hefnawy, Mahmoud T., et al.
Publicado: (2023)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant
por: Karyakarte, Rajesh P, et al.
Publicado: (2023)

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
por: Yao, Lin, et al.
Publicado: (2022)

Old question with new omicron subvariant: Shall we put the masks back on?
por: Ma, Shaodi, et al.
Publicado: (2022)

Omicron B.1.1.529 subvariant: Brief evidence and future prospects
por: Farahat, Ramadan Abdelmoez, et al.
Publicado: (2022)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qcmtq15v8pgdlitfmckj0fbkjh